A blood cancer drug developed by Kazakh scientists is
expected to be tested as early as 2026. Volunteers will be recruited for this
trial. The method is based on CAR-T therapy, which targets and destroys cancer
cells without harming healthy ones. The treatment causes minimal side effects,
and the patient’s immune system is not compromized. Kazakhstan may become the
first country in Central Asia to treat oncological and haematological diseases
using genetically modified cells.
«When using cell therapy involving CAR-T cells, which are
effective at destroying cancer cells, the mechanism is designed to target only
cancer cells, thereby reducing side effects. Compared to drug therapy, this
approach offers blood cancer patients the possibility of a complete cure within
a month. The maximum effect is typically observed around two weeks after the
intravenous infusion of these cells,» noted Vyacheslav Ogay, Acting General
Director of the National Center for Biotechnology.
The drug is one of the projects developed by scientists at
the National Center for Biotechnology, who hold over 230 patents for
inventions. Their developments have been highly praised by international
experts interested in cooperation, including delegations from the World
Intellectual Property Organization, the Eurasian Patent Office, and several specialists
from China, Morocco, Indonesia, Armenia, Azerbaijan, and Tajikistan.
«We were particularly interested in oncohematology.
Advancements in this field mean thousands of lives saved and thousands of
people cured. The fact that the center is conducting such extensive,
world-class work underscores the need for our close cooperation, so that
achievements of this kind can be implemented more rapidly - not only in
Kazakhstan, but especially across the region, ultimately reaching the global
market,» said Grigory Ivliev, President of the Eurasian Patent Office.
Related Articles
